Clinical Trials Logo

Clinical Trial Summary

This study is a prospective study. The subject will select 440 cases of pregnant women with high hepatitis B virus load, and one group will take maternal and child blockade treatment with propofol fumarate. One group will take tenofovir disoproxil fumarate. Broken treatment, compare the failure rate of maternal and child blockade and the incidence of maternal and child adverse events in the two groups, and explore the efficacy and safety of propofol flavuril for the treatment of hepatitis B mother-infant block.


Clinical Trial Description

This study was a prospective cohort study. Because propofolofofovir is not covered by medical insurance and is more expensive, and there are factors such as renal function damage and the risk factors that can not use tenofovir, it is difficult to conduct randomized controlled cases. The subject will select 440 cases of pregnant women with high hepatitis B virus load. After signing the informed consent form, according to the patient's wishes, one group will take the mother-infant blockade of propofol fumarate, and one group will take fumaric acid. In the case of maternal and child blockade of benifovir, the incidence of maternal and child block failure and the incidence of maternal and child adverse events were compared between the two groups, and propofol fumarate was used for maternal and child blockade of hepatitis B. The effectiveness and safety of the treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04135235
Study type Observational
Source Beijing Ditan Hospital
Contact Wei Yi, Doctor
Phone 13683687062
Email yiwei1215@163.com
Status Recruiting
Phase
Start date August 1, 2019
Completion date August 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT03329820 - Quality of Life and Health Utility of Patients With CHB Infections N/A
Recruiting NCT04030039 - Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
Recruiting NCT03209011 - The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03210506 - The Changes of Cytokines During Antiviral Therapy N/A
Recruiting NCT03208998 - The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03209037 - The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03210493 - The Changes of Treg Cells Frequency and Function During Antiviral Therapy N/A
Recruiting NCT03210467 - The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy N/A
Recruiting NCT04638439 - The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection Phase 1
Recruiting NCT03587467 - Study on Gut Microbiota in Chronic HBV Infected Patients
Completed NCT05355467 - Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum Phase 4